Chapter III. Re-establishing Tolerance

Tolerance Strategies Employing Antigen-Coupled Apoptotic Cells and Carboxylated PLG Nanoparticles for the Treatment of Type 1 Diabetes

Suchitra Prasad, Dan Xu, Stephen D. Miller

Manuscript submitted December 15, 2012; resubmitted January 8, 2013; accepted February 8, 2013.

Keywords: type 1 diabetes, immune tolerance, apoptosis, scavenger receptors, poly(lactide-co-glycolide), PLG nanoparticle, anergy, regulatory T cell, transplantation

Abstract

The development of therapies that specifically target autoreactive immune cells for the prevention and treatment of type 1 diabetes (T1D) without inducing generalized immunosuppression that often compromises the host's ability to clear non-self antigen is highly desired. This review discusses the mechanisms and potential therapeutic applications of antigen-specific T cell tolerance techniques using syngeneic apoptotic cellular carriers and synthetic nanoparticles that are covalently cross-linked to diabetogenic peptides or proteins through ethylene carbodiimide (ECDI) to prevent and treat T1D. Experimental models have demonstrated that intravenous injection of autoantigen decorated splenocytes and biodegradable nanoparticles through ECDI fixation effectively induce and maintain antigen-specific T cell abortive activation and anergy by T cell intrinsic and extrinsic mechanisms. The putative mechanisms include, but are not limited to, the uptake and processing of antigen-coupled nanoparticles or apoptotic cellular carriers for tolerogenic presentation by host splenic antigen-presenting cells, the induction of regulatory T cells, and the secretion of immune-suppressive cytokines, such as IL-10 and TGF-β. The safety profile and efficacy of this approach in preclinical animal models of T1D, including non-obese diabetic (NOD), BDC2.5 transgenic, and humanized mice, have been extensively investigated, and will be the focus of this review. Translation of this approach to clinical trials of T1D and other T cell-mediated autoimmune diseases will also be reviewed in this chapter.

Fulltext: HTML , PDF (530KB)

This article has been cited by other articles:

	Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates Pearson RM, Casey LM, Hughes KR, Wang LZ, North MG, Getts DR, Miller SD, Shea LD Mol Ther 2017. In press
	Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation Verbeke CS, Gordo S, Schubert DA, Lewin SA, Desai RM, Dobbins J, Wucherpfennig KW, Mooney DJ Adv Healthc Mater 2017. In press
	Bioengineering strategies for inducing tolerance in autoimmune diabetes Baekkeskov S, Hubbell JA, Phelps EA Adv Drug Deliv Rev 2017. In press
	Regulatory T cell-based therapies for autoimmunity Arellano B, Graber DJ, Sentman CL Discov Med 2016. 22(119):73-80
	An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy McCarthy DP, Yap JW, Harp CT, Song WK, Chen J, Pearson RM, Miller SD, Shea LD Nanomedicine 2016. In press
	Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes Creusot RJ, Battaglia M, Roncarolo MG, Fathman CG Stem Cells 2016. 34(4):809-819
	Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics You S, Chatenoud L Methods Mol Biol 2016. 1371:117-42
	TGF-beta1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice Haribhai D, Luo X, Chen J, Jia S, Shi L, Schroeder JA, Weiler H, Aster RH, Hessner MJ, Hu J, Williams CB, Shi Q Blood Adv 2016. 1(2):139-151
	Immune Tolerance for Autoimmune Disease and Cell Transplantation Luo X, Miller SD, Shea LD Annu Rev Biomed Eng 2016. 18:181-205
	Reversal of New-Onset Type 1 Diabetes With an Agonistic TLR4/MD-2 Monoclonal Antibody Bednar KJ, Tsukamoto H, Kachapati K, Ohta S, Wu Y, Katz JD, Ascherman DP, Ridgway WM Diabetes 2015. 64(10):3614-3626
	Toward beta cell replacement for diabetes Johannesson B, Sui L, Freytes DO, Creusot RJ, Egli D EMBO J 2015. 34(7):841-855
	Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases Sauer EL, Cloake NC, Greer JM Int Rev Immunol 2015. 34(6):460-485
	Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction Gharagozloo M, Majewski S, Foldvari M Nanomedicine 2015. 11(4):1003-1018